Denifanstat should help back acne because it works throughout the body, but its published trial results focus on facial acne. Denifanstat is an oral, once-daily small-molecule inhibitor of fatty acid synthase (FASN), an enzyme involved in skin-oil production.
That whole-body action matters for the back and chest. Those areas are wide, often sweaty, and hard to cover with creams. An oral treatment that lowers oil and inflammation can reach them in a way spot treatments often miss.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How denifanstat fights acne
- What the trials measured
- Why back acne is expected to respond
- What to do if back acne is your main concern
How denifanstat fights acne
Denifanstat blocks FASN and reduces de novo lipogenesis, sebum lipid production, and inflammation driving acne. HCPLive describes this oil-lowering mechanism in its 52-week denifanstat update. Less excess oil means fewer clogged pores.
Less inflammation means fewer red, painful breakouts. Facial and back acne share the same drivers: excess sebum, clogged follicles, bacteria, and inflammation. A drug taken by mouth circulates systemically. It does not need to be rubbed across every back lesion.
What the trials measured
The parent Phase 3 trial ASC40-303 in China randomized 480 patients with moderate-to-severe acne vulgaris to denifanstat 50 mg daily or placebo for 12 weeks. It met all primary and secondary endpoints. Reported scores used facial and global Investigator's Global Assessment and facial lesion counts.
Longer treatment kept improving acne. In extension study ASC40-304, 240 prior participants took 50 mg daily for up to 40 more weeks, Dermatology Times reports in its 52-week extension results. Success reached about 57% for Investigator's Global Assessment, with 72% fewer total lesions and 77% fewer inflammatory lesions at up to 52 weeks.
Why back acne is expected to respond
Body acne is expected to respond to therapy just as facial acne would. A Practical Dermatology review states that truncal and facial acne are pathophysiologically the same in its review of truncal acne options. The same review notes systemic drugs are often preferred because large back and chest areas are hard to treat topically.
Another oral drug sets a useful precedent. Pooled Phase 3 data found oral sarecycline improved chest and back acne as early as three weeks, with continued improvement over the study. That pattern supports the idea that facial-trial efficacy can translate to the trunk.
What to do if back acne is your main concern
Denifanstat remains investigational for acne and is not yet a prescription option. China's application was accepted in December 2025, and Sagimet's U.S.
Phase 3 AURORA trial began dosing with topline results expected in the second half of 2027. Ask a dermatologist for a plan that treats the face and trunk together:.
- Describe where breakouts occur: back, chest, shoulders, jawline, or all areas
- Mention friction triggers: backpacks, sports pads, tight workout tops, and delayed showering
- Review current prescriptions, over-the-counter washes, and how consistently large areas can be treated
- Discuss oral options when breakouts are widespread, severe, painful, or leaving dark marks and scars